Get the latest news, insights, and market updates on COO (The Cooper Companies, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
3 Reasons to Sell COO and 1 Stock to Buy Instead
Over the past six months, CooperCompanies has been a great trade, beating the S&P 500 by 5.9%. Its stock price has climbed to $82.42, representing a healthy 19.9% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation. Dec 17, 2025 - $COO
5 Insightful Analyst Questions From CooperCompanies’s Q3 Earnings Call
CooperCompanies delivered a third quarter that met market expectations, with management highlighting robust execution in its premium daily contact lens portfolio and steady contract wins in both private label and branded products. CEO Al White attributed the performance to the global rollout of the MyDay lens line, stating, “Momentum is robust, we’re seeing increasing bidding activity with especially strong interest in our premium comfort MyDay Energous lens.” Despite ongoing softness in the Asi Dec 11, 2025 - $COO
Is The Cooper Companies Stock Underperforming the Nasdaq?
Even though The Cooper Companies has underperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects. Dec 11, 2025 - $COO
Does Cooper Companies Recent Rebound Reflect Its True Value In 2025?
If you are wondering whether Cooper Companies is a quietly mispriced opportunity or a potential value trap, you are not alone. That is exactly what we are going to unpack here. The stock has bounced about 0.8% over the last week and 11.3% over the past month. However, that is still against a backdrop of a -13.9% return year to date and -21.4% over the last year. Recent headlines have focused on Cooper Companies strategic positioning in specialty contact lenses and women’s health, along with... Dec 9, 2025 - $COO
COO Q3 Deep Dive: Product Momentum and Strategic Review Shape Outlook
Medical device company CooperCompanies (NASDAQ:COO) met Wall Streets revenue expectations in Q3 CY2025, with sales up 4.6% year on year to $1.07 billion. The company expects next quarter’s revenue to be around $1.02 billion, coming in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.15 per share was 3.2% above analysts’ consensus estimates. Dec 5, 2025 - $COO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple